What Does NICE Say About Using GLP-1 with Specialist Services?

GLP-1 medicines have become a prominent option for weight management, but they are not intended to replace ongoing care. In England, NICE recommends semaglutide for some adults living with obesity only as part of a specialist weight-management service, alongside a reduced-calorie diet and increased physical activity. That specialist programme requirement is central to understanding who may be offered treatment, what support should accompany it, and how progress and side effects are managed.

This guide explains how GLP-1 receptor agonists work, what clinical trials have found, how NICE eligibility rules are generally applied, and why structured support matters. It also distinguishes Wegovy, the semaglutide product NICE recommends for weight management, from Ozempic, a semaglutide brand used for type 2 diabetes.

What are GLP-1 receptor agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone involved in regulating appetite and blood glucose. GLP-1 receptor agonists are medicines that act on pathways responding to this hormone. Semaglutide is one such medicine. It can help people feel fuller for longer, reduce hunger and cravings, and slow the movement of food out of the stomach. These effects can make it easier to eat less, though individual experiences vary.

Semaglutide is not a stand-alone solution: its effects are intended to support changes in eating and activity, not to make those changes unnecessary. It is given as a weekly injection and usually started at a low dose that is increased gradually. Gradual dose escalation helps people adjust and may reduce gastrointestinal side effects.

Wegovy and Ozempic: related medicine, different use

Wegovy is the semaglutide brand used for weight management in the NICE recommendation discussed here. Ozempic is a semaglutide brand licensed for type 2 diabetes; it should not be assumed to be interchangeable with Wegovy or prescribed for weight management outside the appropriate clinical and regulatory framework. Brand, dose, indication, and supply arrangements matter. A clinician or pharmacist can explain which product is appropriate for a person’s circumstances.

What does the evidence say?

The STEP clinical trial programme studied semaglutide for weight management in adults with overweight or obesity. In STEP 1, participants without diabetes received semaglutide or placebo alongside lifestyle support for 68 weeks. Average weight loss was about 14.9% in the semaglutide group, compared with about 2.4% in the placebo group. These are group averages, not a prediction of what any one person will achieve.

Other randomised controlled trials (RCTs) have helped answer different questions. STEP 4 examined what happened when people who had already taken semaglutide for an initial period either continued treatment or switched to placebo. Those who continued generally maintained or increased weight loss, while the group switching to placebo regained weight on average. STEP 5 followed participants for two years and found that weight loss was broadly sustained for many people who remained on treatment.

Taken together, these trials show that semaglutide can be effective for weight management when used alongside lifestyle support. They also show why treatment should be considered in the context of longer-term care: stopping the medicine may be followed by weight regain. Trial results do not mean everyone will respond in the same way, and trial participation is not the same as routine NHS care. Clinical decisions need to account for eligibility, benefits, risks, preferences, and available services.

NICE guidance and the specialist programme requirement

NICE technology appraisal TA875 recommends semaglutide, alongside a reduced-calorie diet and increased physical activity, as an option for some adults with at least one weight-related condition. The recommendation is for use within a specialist weight-management service. I remember a project where learned this lesson the hard way.. In practice, that means the medicine is one element of a broader programme, rather than a prescription intended to stand alone.

NICE’s recommendation NHS weight management service is time-limited: semaglutide should be used for a maximum of two years under this guidance. A specialist service can assess suitability, support dose escalation, help with nutrition and activity changes, monitor response and side effects, and plan what happens as treatment ends. Availability and referral pathways can differ between areas, so a GP or local NHS weight-management service is often the best starting point for checking current arrangements.

Who may meet the eligibility rules?

Under the NICE recommendation, adults generally need to meet the following criteria:

• Have a body mass index (BMI) of at least 35 kg/m2 and at least one weight-related comorbidity, such as type 2 diabetes, high blood pressure, or abnormal blood fats; or
• Have a BMI from 30 to 34.9 kg/m2 and meet the criteria for referral to a specialist weight-management service.

NICE advises using lower BMI thresholds for people from some ethnic backgrounds because health risks associated with excess weight can occur at a lower BMI. The relevant threshold is generally reduced by 2.5 kg/m2. BMI is only one part of assessment: a clinician may also consider a person’s health conditions, medicines, history, and individual circumstances.

Meeting a BMI threshold does not automatically guarantee treatment. The person must also meet the service’s referral and clinical criteria, and a specialist team must decide that treatment is suitable. Local capacity, commissioning arrangements, and referral routes can affect access. These practical factors are worth discussing with an NHS clinician rather than relying on general information alone.

NICE consideration What it means in practice Weight-related health condition Assessment includes whether a relevant comorbidity is present. BMI and ethnic background Thresholds may be lower for some ethnic groups; BMI is not the only factor. Specialist service Semaglutide is recommended as part of a specialist weight-management programme. Duration NICE guidance specifies a maximum treatment period of two years.

Why structured support matters

A specialist programme can provide more than check-ins about weight. It may help someone build practical routines around meals, movement, sleep, and coping with changes in appetite. It can also give people a place to raise concerns early, adjust treatment with a prescriber, and set realistic goals that are not limited to the number on the scales.

Structured support is particularly important because appetite and food intake may change substantially. Some people need guidance on maintaining adequate nutrition and hydration, managing smaller portions, or adapting activity as weight changes. A dietitian, pharmacist, GP, or specialist clinician may contribute, depending on the service. The aim is individualised care—not a one-size-fits-all diet plan.

It is also useful to discuss the end of treatment before starting. Because weight regain can occur after stopping, a team can help plan ongoing habits and follow-up. This does not guarantee that weight will be maintained, but it can make the transition more considered and supported.

Side effects and monitoring

The most commonly reported side effects of semaglutide include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. These symptoms are often more noticeable when treatment starts or the dose increases, and may improve over time. Eating smaller meals, taking time to eat, and staying hydrated may help some people, but persistent or severe symptoms should be discussed with a healthcare professional.

Less common but potentially serious problems can occur. Severe, persistent abdominal pain, especially with vomiting, needs urgent medical advice. A clinician should also be told about new or worsening symptoms, difficulty keeping fluids down, or signs of an allergic reaction. The prescriber can explain the full safety information and whether a person’s medical history or other medicines affect suitability.

What monitoring may involve

• Reviewing medical history, weight-related conditions, and current medicines before treatment.
• Checking tolerance and side effects during gradual dose increases.
• Assessing weight change and other relevant health measures over time.
• Discussing nutrition, hydration, physical activity, and any difficulties with eating.
• Reconsidering the plan if side effects are troublesome or the expected benefit is not being achieved.

Monitoring should be proportionate and tailored to the individual. Do not change the dose, stop treatment, or combine weight-loss medicines without advice from the prescribing team. People who are pregnant, planning a pregnancy, or breastfeeding should discuss treatment with a clinician; semaglutide is not a medicine to use casually in these circumstances.

Online marketplaces and social media: use caution

Online marketplaces and social media channels can make GLP-1 medicines appear easy to obtain, and posts may promise rapid or effortless weight loss. These claims can leave out eligibility rules, side effects, dose escalation, and the need for follow-up. Medicines from unregulated sources may be counterfeit, improperly stored, or supplied without a proper assessment.

Use a regulated healthcare provider and a legitimate pharmacy, and check that a prescriber is appropriately qualified. Avoid buying prescription medicines from informal sellers or using another person’s supply. If an online service is offering semaglutide, ask who will assess you, who will prescribe it, what monitoring is included, and how to contact a clinician if problems arise.

Questions to ask a healthcare professional

1. Do I meet NICE’s eligibility rules, including the relevant BMI threshold and health criteria?
2. Is a specialist weight-management service available locally, and how do I access it?
3. What benefits and risks are most relevant to my health history and current medicines?
4. What support will I receive with nutrition, activity, side effects, and follow-up?
5. How will we plan for the end of treatment or a change in treatment?

The bottom line

NICE supports semaglutide for weight management for some adults who meet defined eligibility criteria, but within a specialist service and alongside changes to diet and physical activity. The specialist programme requirement is not a minor administrative detail: it reflects the role of assessment, monitoring, and structured support during treatment. STEP trials and other RCTs show meaningful average weight loss for many participants, while also highlighting that responses differ and weight regain may follow discontinuation.

Eligibility rules, local NHS pathways, and individual medical considerations all matter. If you are considering treatment, speak with a qualified clinician rather than relying on social media claims or unverified online marketplaces. They can help clarify whether Wegovy is suitable, distinguish it from Ozempic, and identify the safest route to appropriate support.

This article is for general information and is not a substitute for personalised medical advice. NICE guidance and local service arrangements can change; check current guidance and speak with an NHS clinician or pharmacist about your circumstances.